Lifeboat Foundation

The AHA names evolocumab — a new PCSK9 inhibitor — as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8, 2018. However, this novel cholesterol-lowering drug carries a big price tag.

Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances in heart disease and stroke research, published on February 8. Evolocumab belongs to a class of cholesterol-lowering drugs called PCSK9 inhibitors and is injectable drug marketed by Amgen under the brand name Repatha. The two-year FOURIER study reported that evolocumab reduced high cholesterol levels and had few adverse effects.

Continue reading “AHA names PCSK9 inhibitor evolocumab as a top advance in heart disease” »

In a first for medical science, scientists in the UK have successfully created functioning human kidney tissue that produces urine.

Summary: In a first for medical science, researchers in the UK have successfully created functioning human kidney tissue that produces urine. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

In a first for medical science, researchers have successfully created human kidney tissue within a living organism which can produce urine.

Continue reading “Researchers create functioning kidney tissue” »

Researchers just reported promising rapamycin clinical trial results in the first of its kind test of the drug’s safety and anti-aging effects on healthy Senior adults. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

A rapamycin clinical trial using healthy adults recently completed and reported the drug to be safe over the short-term when used for anti-aging purposes.

This clinical trial of rapamycin was one of the first testing the compound’s safety as an anti-aging drug in healthy Seniors. The clinical trial consisted of 25 healthy older adults 70–95 years between the ages of 70 to 95. The study participants took either a placebo or 1mg rapamycin daily for eight weeks. The main finding of the study was that the drug was safe, without significant side effects. The researchers published their results on February 3 in the journal Experimental Gerontology and concluded.

Continue reading “Researchers report promising anti-aging rapamycin clinical trial results” »

A Japanese scientist regrows hair follicles at record rate using a special ingredient – this novel technique could revolutionize the treatment of baldness. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

While scientists aim to lengthen our lifespans, at least they can lengthen our locks.

Or even grow a full head of hair on a bald pate, in the near future.

A scientist gets to the roots of hair loss in a study published at the end of January, saying baldness is due to metabolic changes and free radical damage – and suggests ways to solve the problem. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

Why We Grow Bald

Scientists have identified at least nine mechanisms that underly the aging process, the so-called hallmarks of aging. While there are many factors that contribute to baldness, including hormonal changes, two of these hallmarks have been implicated in age-related hair loss in women in a study published in late January of this year.

February 21st Dr. Oliver Medvedik is hosting a special AI vs Aging Livestream here on our Facebook page. Anastasia Georgievskaya, Alex Zhavoronkov, and guests will be taking part in this special panel focusing on AI in aging research.

Ask your questions about AI in research on the thread here and we will try to include them in the show.

So will we ever be able to do this or is this just a pipe dream? Plenty has been written about the future and what we may be able to do one day, but not much attention gets paid to the hurdles we have yet to overcome. Forget all the techno-babble, philosophy, and transhumanism – how close is this brave new world to our present time?

“Any way you look at it, all the information that a person accumulates in a lifetime is just a drop in a bucket.”

Continue reading “Humans Could Soon Become Immortal, But The Cost May Be Horrifying. Would You Do It?” »

Summary: Clues to the naked mole rat’s remarkable cancer-fighting abilities have been uncovered by researchers at the University of Rochester in a new study. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

With their wrinkled, hairless bodies, naked mole rats won’t be winning any beauty contests.

However, they do win longevity contests.

Continue reading “The key to a naked mole rat’s cancer-free life?” »

Summary: Researchers discover what may be the key to stopping uncontrolled inflammation and the damage it causes in a multitude of chronic diseases. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

A discovery by researchers at the University of Queensland (UQ) could be the key to stopping the damage caused by uncontrolled inflammation in a range of chronic diseases including Alzheimer’s and liver disease.

Queensland scientists have uncovered how an inflammation process automatically switches off in healthy cells, and are now investigating ways to stop it when it runs amok. The finding may lead to a way to turn off chronic low-grade inflammation without interfering with the body’s natural defenses against infection.

Continue reading “Researchers discover off-switch to inflammation machine at the root of our chronic diseases” »